1.
Efficacy of recombinant human interleukin-11 in preventing and treating oral mucositis after chemotherapy for patients with acute leukemia.
Zhang, Y, Li, Y, He, A, Wang, J, Zhang, P, Lei, B, Huang, Z, Zhang, L, Zhao, W, Ma, X
BMC oral health. 2023;(1):476
Abstract
OBJECTIVE This study aimed to investigate the clinical effects of recombinant human interleukin-11 (rhIL-11) gargle on preventing and treating oral mucositis (OM) after chemotherapy for acute leukemia. METHODS This single-site, prospective, observer-blinded, nonrandomized controlled trial was conducted on 74 patients with acute leukemia, who were divided into the experimental and control groups. The patients in the experimental group were treated with IL-11 gargle, and those in the control group were treated with sodium bicarbonate gargle. We examined the time and severity of oral mucositis, severity and duration of associated pain, healing time of mucositis, effects of OM on eating, and levels of T-cell subset indicators before and after treatment to evaluate the effects of IL-11 treatment. RESULTS The proportion of patients with severe OM was significantly lower in the experimental group than in the control group. Mucositis occurred later in the experimental group compared with the control group. The degree and duration of pain, ulcer healing time, and effects on eating were lower in the experimental group compared with the control group. Following treatment, the levels of all T-cell subset indicators improved in each of the two groups. However, the rate of improvement was significantly higher in the experimental group than in the control group. These differences were statistically significant (Pā<ā0.05). CONCLUSIONS IL-11 gargle reduced the severity of OM after chemotherapy for acute leukemia. Treatment with IL-11 relieved pain, promoted healing, and improved the curative effect of the condition, making it worthy of clinical promotion.
2.
Danshen extracts decrease blood C reactive protein and prevent ischemic stroke recurrence: a controlled pilot study.
Xu, G, Zhao, W, Zhou, Z, Zhang, R, Zhu, W, Liu, X
Phytotherapy research : PTR. 2009;(12):1721-5
Abstract
The efficacy of a danshen (Salvia miltiorrhiza) dripping pill (DDP) for secondary stroke prevention was evaluated in patients with ischemic cerebrovascular disease. The preparation also contained Panax notoginseng (sanqi) and Dryobalanops camphor. Patients who had suffered from ischemic stroke or a transient ischemic attack (TIA) within the previous 20 days were managed according to established guidelines, and were divided into groups to receive either DDP or non-DDP treatment according to their time of enrolment. Mortality, cerebrovascular events and any suspected adverse reactions during the 1-year follow-up were recorded and analysed. Hematological and hemorheological parameters were measured at the start of the study (baseline) and the end of the follow-up period. A total of 106 patients with ischemic stroke/TIA were enrolled, of which 52 were allocated to take DDP and 54 were in the control group. Recurrent stroke/TIA was observed in five patients (9.6%) with DDP and in 13 patients (24.1%) without DDP during the follow-up. Recurrence in the patient group taking DDP was lower than that in the control group (p<0.05). No significant differences in intracranial hemorrhage and mortality were detected between groups (p>0.05). Blood C reactive protein decreased significantly in patients with DDP compared with patients without DDP. These results indicate that DDP treatment may reduce the risk for stroke/TIA recurrence, and this reduction of risk may be associated with its antiinflammatory effects.
3.
Use of allogenic acellular dermal matrix in prevention of Frey's syndrome after parotidectomy.
Ye, WM, Zhu, HG, Zheng, JW, Wang, XD, Zhao, W, Zhong, LP, Zhang, ZY
The British journal of oral & maxillofacial surgery. 2008;(8):649-52
Abstract
OBJECTIVE To evaluate the use of an allogenic acellular dermal matrix (ADM) as an interpositional graft to prevent Frey's syndrome after parotidectomy. METHOD We studied a total of 168 patients with benign parotid gland tumours, including 89 patients with pleomorphic adenoma; 45 with Warthin tumour; 17 with basal cell adenoma; and 17 with miscellaneous tumours. The patients were divided into two groups: the first (control n=104) had superficial or partial parotidectomy alone, and the second (experimental n=64), had superficial or partial parotidectomy with simultaneous placement of an ADM graft. All patients were evaluated for gustatory sweating by clinical examination. For objective assessment, 60 patients (30 from each group) were randomly selected for a starch-iodine test. RESULTS Subjectively Frey's syndrome was recorded in 63 patients (61%) from the controls and one patient (2%) from the ADM group. Objectively Frey's syndrome was found in 24 patients from the control group (23%) and 2 patients from the ADM group (2%). Salivary fistulas developed in 18 patients from the control group (17%), but in only 1 patient from the ADM group (2%). Both differences were P<0.05, but there was no significant difference between superficial parotidectomy and partial superficial parotidectomy (P=0.714). CONCLUSION The use of acellular dermal matrix (ADM) as an interpositional graft is an effective way of preventing Frey's syndrome after parotidectomy.